このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Prelude Therapeutics 将来の成長

Future 基準チェック /06

Prelude Therapeuticsの収益は年間7.1%で減少すると予測されていますが、年間収益は年間79.8%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-122.6% 7.8%なると予測されています。

主要情報

-7.1%

収益成長率

7.8%

EPS成長率

Biotechs 収益成長	24.2%
収益成長率	79.8%
将来の株主資本利益率	-122.6%
アナリストカバレッジ	Low
最終更新日	08 May 2024

今後の成長に関する最新情報

Recent updates

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25

業績と収益の成長予測

NasdaqGS:PRLD - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-158	N/A	N/A	1
12/31/2025	N/A	-138	N/A	N/A	1
12/31/2024	N/A	-128	N/A	N/A	2
3/31/2024	N/A	-126	-112	-109	N/A
12/31/2023	N/A	-122	-111	-107	N/A
9/30/2023	N/A	-117	-109	-106	N/A
6/30/2023	N/A	-117	-104	-101	N/A
3/31/2023	N/A	-114	-95	-92	N/A
12/31/2022	N/A	-115	-87	-84	N/A
9/30/2022	N/A	-120	-89	-87	N/A
6/30/2022	N/A	-120	-91	-88	N/A
3/31/2022	N/A	-120	-92	-89	N/A
12/31/2021	N/A	-112	-86	-84	N/A
9/30/2021	N/A	-98	-75	-73	N/A
6/30/2021	N/A	-84	-65	-63	N/A
3/31/2021	N/A	-69	-54	-52	N/A
12/31/2020	N/A	-57	-47	-46	N/A
9/30/2020	N/A	-48	-40	-40	N/A
6/30/2020	N/A	-38	-34	-33	N/A
3/31/2020	N/A	-32	-31	-30	N/A
12/31/2019	N/A	-28	-26	-26	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PRLD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PRLD今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PRLD今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PRLD来年は収益がないと予測されています。

高い収益成長: PRLD来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PRLD 3 年以内に赤字になると予測されています。

Prelude Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 9.7% to US$7.00

Price target decreased by 22% to US$7.75

Price target decreased to US$9.60

Price target decreased to US$11.60

Price target increased to US$30.00

Price target decreased to US$25.25

Recent updates

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 14, 2024

Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Insufficient new directors

Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding

Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding

New major risk - Revenue and earnings growth

Price target decreased by 9.7% to US$7.00

New minor risk - Market cap size

Price target decreased by 22% to US$7.75

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

New minor risk - Share price stability

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Founder recently bought US$67k worth of stock

President & Chief Medical Officer exercised options and sold US$81k worth of stock

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Founder recently bought US$98k worth of stock

Price target decreased to US$9.60

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Prelude downgraded at Morgan Stanley ahead of key update

Price target decreased to US$11.60

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 2000 Growth Index

Price target increased to US$30.00

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 17, 2022

Price target decreased to US$25.25

Deborah Morosini Resigns as an Officer of Prelude Therapeutics Incorporated and Will Transition into a Role of Strategic Advisor to the President

Executive VP & Head of Chemistry exercised options to buy US$237k worth of stock.

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Price target increased to US$44.00

Price target decreased to US$38.00

Executive VP & Head of Chemistry recently bought US$95k worth of stock

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Chief Financial Officer Brian Piper has left the company

Insider exercised options and sold US$87k worth of stock

Price target decreased to US$47.20

Chief Medical Officer exercised options and sold US$436k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$77k worth of stock

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$681k worth of stock

Chief Medical Officer exercised options and sold US$384k worth of stock

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 3000E Value Index

Chief Medical Officer exercised options and sold US$458k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$574k worth of stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Chief Medical Officer exercised options and sold US$725k worth of stock

Chief Medical Officer notifies of intention to sell stock

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

New 90-day high: US$90.03

Prelude Therapeutics Incorporated Announces Board Changes

Independent Director has left the company

Prelude Therapeutics Incorporated has completed a Follow-on Equity Offering in the amount of $150 million.

Prelude Therapeutics prices $150M share offering

Prelude Therapeutics readies public offering

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic Malignancies

Prelude Therapeutics Incorporated has completed an IPO in the amount of $158.175 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘